Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of tau to monitor immunotherapy

a technology of immunotherapy and tau, applied in the direction of antibody medical ingredients, instruments, peptides, etc., can solve the problems of neuronal cell death and unroutinely performed genetic screening for e4 , to improve the safety of bapineuzumab

Active Publication Date: 2015-04-30
WYETH LLC +1
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The tailored antibody regimen effectively reduces cognitive decline and brain volume loss in ApoE4 non-carriers while minimizing the risk of vasogenic edema in ApoE4 carriers, providing a safer and more effective treatment strategy for Alzheimer's disease management.

Problems solved by technology

Accumulation of amyloid plaques in the brain eventually leads to neuronal cell death.
Nonetheless, even persons with two E4 alleles do not always get Alzheimer's disease.
Genetic screening for E4 has not been routinely performed, because it has not been known how to use this information for a therapeutic regime.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of tau to monitor immunotherapy
  • Use of tau to monitor immunotherapy
  • Use of tau to monitor immunotherapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Phase 1 Trial

[0348]111 patients with a diagnosis of probable Alzheimer's disease (mild to moderate) were administered the humanized antibody bapineuzumab at doses ranging from 0.15 to 2.0 mg / kg in a multiple ascending dose study (MAD). Antibody was administered by intravenous infusion every thirteen weeks until the dosing regime is complete. Patients were also classified for ApoE4 status. Table 2 shows that eleven patients in the study experienced vasogenic edema detected by MRI. Table 2 also shows symptoms experienced in some of these patients; in other patients the vasogenic edema was asymptomatic. Table 3 shows the risk of vasogenic edema stratified by genotype irrespective of dose. The risk is only 2% in patients lacking an E4 allele but is 35% in patients with two E4 alleles. Table 4 shows the risk of vasogenic edema in only the highest dose group (2 mg / kg). The risk of vasogenic edema for patients with two E4 alleles is 60% and that for patients with one allele is 35%.

[0349]Ta...

example 2

Phase 2 Trial, Study 201

[0350]A randomized double-blind placebo-controlled multiple ascending dose study was conducted on a population of 234 patients randomized from an initial population of 317 screened patients. Patients were assessed for ApoE4 carrier status, but carriers (homozygous and heterozygous) and non-carriers received the same treatment. Inclusion criteria were: probable AD diagnosis; aged 50-85 years; MMSE score 16-26; Rosen Modified Hachinski Ischemic score≦4; Living at home or in a community dwelling with a capable caregiver; MRI consistent with diagnosis of AD; MRI scan of sufficient quality for volumetric analysis; stable doses of medication for treatment of non-excluded conditions; stable doses of AchEIs and / or memantine for 120 days prior to screen. The main exclusion criteria were: current manifestation of a major psychiatric disorder (e.g., major depressive disorder); current systemic illness likely to result in deterioration of the patient's condition; history...

example 2b

Phase II Clinical Trial 202

[0373]The clinical trial was a phase 2, multicenter, randomized, double-blind, placebo-controlled, multiple-ascending dose study. Patients were randomly assigned to receive either intravenous (IV) bapineuzumab or placebo, in one of three dose cohorts (0.5 [A], 1.0 [B], or 2.0 [C] mg / kg). Up to 30 patients were planned for enrollment (10 per dose cohort with patients in each dose cohort [A, B, or C] receiving bapineuzumab or placebo in a 7:3 ratio). Patients who completed the screening phase and met all inclusion criteria were eligible for randomization. 28 patients were enrolled in the study (10 in cohort A, 10 in cohort B and eight in cohort C). The sponsor terminated enrollment in cohort C following the observation of more frequent cerebral vasogenic edema at the 2.0 mg / kg dose in other studies. Randomized patients received study drug as a 1-hour IV infusion every 13 weeks for up to six infusions. Each patient underwent [11C]PiB PET, [18F]FDG PET, clinic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered is monitored by measuring levels of tau.

Description

CROSS-REFERENCE TO RELATED APPLICATION[0001]This application claims priority from U.S. Application No. 61 / 327,062, filed Apr. 22, 2010 and U.S. Application No. 61 / 450,619, filed Mar. 8, 2011, each of which is incorporated by reference in its entirety for all purposes. This application is related to U.S. Application No. 60 / 999,423, filed Oct. 17, 2007, U.S. Application No. 61 / 083,827 filed Jul. 25, 2008, and WO / 2009 / 052439, filed Oct. 17, 2008. Each of the above applications is incorporated by reference in its entirety for all purposes.REFERENCE TO A SEQUENCE LISTING[0002]The Sequence Listing written in file Sequence Listing for 057436-404683.txt is 164,718 bytes and was created on Apr. 22, 2011. The information contained in this file is hereby incorporated by reference.BACKGROUND OF THE INVENTIONI. General[0003]Alzheimer's disease (AD) is a progressive disease resulting in senile dementia. See generally Selkoe, TINS 16:403 (1993); Hardy et al., WO 92 / 13069; Selkoe, J. Neuropathol. E...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395
CPCA61K39/3955A61K2039/505C07K16/18C07K2317/24C07K2317/34A61K2039/545A61K2039/55
Inventor BLACK, RONALDJACOBSEN, JACK STEVENTCHISTIAKOVA, LIOUDMILAWIDOM, ANGELAGILL, DAVINDEREKMAN, LARSLIEBERBURG, IVANGRUNDMAN, MICHAELCALLAWAY, JAMESGREGG, KEITH M.ZAGO, WAGNERBUTTINI, MANUEL J.KINNEY, GENE G.
Owner WYETH LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com